Metraipolis › archive › dc_ffacc78a3ef0

Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group) — Europe PMC PMID:41992826

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41992826
DOI
10.1111/liv.70640
License (as archived)
solo-consultazione
Archived
2026-11-02T20:41:09.883Z
SHA-256 of the archived text
656eaa344e0104b5624474df61ce3590057e4eccf91f3dcf5ca42366d22e6b85
Stable URL of this page
https://metraipolis.com/documento/dc_ffacc78a3ef0

How to cite

Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group) — Europe PMC PMID:41992826 — Europe PMC (en), https://europepmc.org/article/MED/41992826 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ffacc78a3ef0 (Metraipolis archive dc_ffacc78a3ef0, sha256 656eaa344e0104b5624474df61ce3590057e4eccf91f3dcf5ca42366d22e6b85)
BibTeX
@misc{dcffacc78a3ef0,
  title = {Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group) — Europe PMC PMID:41992826},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41992826},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ffacc78a3ef0; sha256 656eaa344e0104b5624474df61ce3590057e4eccf91f3dcf5ca42366d22e6b85},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41992826. Agents can read the archived copy with the MCP tool read_document.